PharmAla Biotech (CSE:MDMA) CEO Nick Kadysh joined Steve Darling from Proactive to share news the company has signed a deal with Global Wellness Strategies to provide MDMA for a clinical trial in Australia.
Kadysh telling Proactive PharmAla Biotech (CSE:MDMA) is the only company currently manufacturing a finished clinical grade of MDMA Drug Product in North America. Kadysh also shared with Proactive the company has initiated preclinical research on its patented novel chemical entities at the laboratory of Dr. William Fantegrossi at the University of Arkansas for Medical Sciences.